Patents by Inventor C. Simone Jude-Fishburn

C. Simone Jude-Fishburn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190070251
    Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.
    Type: Application
    Filed: April 28, 2017
    Publication date: March 7, 2019
    Inventors: Mary J. Bossard, Steven O. Roczniak, Harold Zappe, Yujun Wang, Ping Zhang, Dawei Sheng, C. Simone Jude-Fishburn, Elizabeth Louise Minamitani, Xiaofeng Liu, Haim Moskowitz, Dennis G. Fry, Cherie F. Ali, Christine Taylor Brew
  • Publication number: 20180353609
    Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.
    Type: Application
    Filed: August 21, 2018
    Publication date: December 13, 2018
    Inventors: C. Simone Jude-Fishburn, Laurie A. VanderVeen, Timothy A. Riley
  • Patent number: 10092656
    Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: October 9, 2018
    Assignee: Nektar Therapeutics
    Inventors: C. Simone Jude-Fishburn, Laurie A. VanderVeen, Timothy A. Riley
  • Patent number: 9682153
    Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: June 20, 2017
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Steven O. Roczniak, Harold Zappe, Yujun Wang, Ping Zhang, Dawei Sheng, C. Simone Jude-Fishburn, Elizabeth Louise Minamitani, Xiaofeng Liu, Haim Moskowitz, Dennis G. Fry, Cherie F. Ali, Christine Taylor Brew
  • Publication number: 20170028077
    Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.
    Type: Application
    Filed: August 4, 2016
    Publication date: February 2, 2017
    Inventors: C. Simone Jude-Fishburn, Laurie A. VanderVeen, Timothy A. Riley
  • Publication number: 20160243111
    Abstract: The invention provides opioid agonists covalently bound to a water-soluble oligomer having reduced potential for substance abuse and uses thereof. The compounds of the invention possess altered pharmacokinetic profiles relative to the opioid agonists alone, but are not subject to the risk of physical tampering that allows for the recovery and abuse of the opioid agonist associated with certain alternative delivery formulations.
    Type: Application
    Filed: February 18, 2016
    Publication date: August 25, 2016
    Inventors: C. Simone Jude-Fishburn, Timothy A. Riley, Alberto N. Zacarias, Hema Gursahani
  • Publication number: 20160022828
    Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.
    Type: Application
    Filed: March 20, 2015
    Publication date: January 28, 2016
    Inventors: Mary J. Bossard, Steven O. Roczniak, Harold Zappe, Yujun Wang, Ping Zhang, Dawei Sheng, C. Simone Jude-Fishburn, Elizabeth Louise Minamitani, Xiaofeng Liu, Haim Moskowitz, Dennis G. Fry, Cherie F. Ali, Christine Taylor Brew
  • Patent number: 9155797
    Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: October 13, 2015
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
  • Publication number: 20140329895
    Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.
    Type: Application
    Filed: July 22, 2014
    Publication date: November 6, 2014
    Inventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
  • Patent number: 8829043
    Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: September 9, 2014
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
  • Publication number: 20130023553
    Abstract: Provided are methods for reducing the addiction potential and/or reducing one or more CNS-side effects related to the administration of an opioid analgesic drug by administering the opioid analgesic drug in the form of an oligomeric polyethylene glycol conjugate compound. The compounds provided demonstrate notably reduced potential for substance abuse, and possess altered pharmacokinetic profiles relative to the opioid agonists alone, but are not subject to the risk of physical tampering that allows for the recovery and abuse of the opioid agonist associated with certain alternative delivery formulations.
    Type: Application
    Filed: January 12, 2011
    Publication date: January 24, 2013
    Applicant: Nektar Therapeutics
    Inventors: C. Simone Jude-Fishburn, Timothy A. Riley, Alberto N. Zacarias, Hema Gursahani
  • Publication number: 20120022063
    Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.
    Type: Application
    Filed: February 6, 2009
    Publication date: January 26, 2012
    Applicant: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
  • Publication number: 20110237614
    Abstract: The invention provides opioid agonists covalently bound to a water-soluble oligomer having reduced potential for substance abuse and uses thereof. The compounds of the invention possess altered pharmacokinetic profiles relative to the opioid agonists alone, but are not subject to the risk of physical tampering that allows for the recovery and abuse of the opioid agonist associated with certain alternative delivery formulations.
    Type: Application
    Filed: September 16, 2009
    Publication date: September 29, 2011
    Applicant: Nektar Therapeutics
    Inventors: C. Simone Jude-Fishburn, Timothy A. Riley, Alberto N. Zacarias, Hema Gursahani
  • Publication number: 20110195940
    Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature. Exemplary potent HIV protease inhibitors are mono-m-PEG3-atazanavir, mPEGn-N-darunavir (wherein n is 3 or 5), mPEGn-NHCO-saquinavir (wherein n is 5 or 7), and di-mPEG3-atazanavir.
    Type: Application
    Filed: September 17, 2009
    Publication date: August 11, 2011
    Applicant: Nektar Therapeutics
    Inventors: C. Simone Jude-Fishburn, Laurie A. Vander Veen, Timothy A. Riley
  • Publication number: 20110171163
    Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.
    Type: Application
    Filed: September 17, 2009
    Publication date: July 14, 2011
    Applicant: Nektar Therapeutics
    Inventors: Dawei Sheng, Harold Zappe, C. Simone Jude-Fishburn, Steven O. Roczniak, Mary J. Bossard
  • Publication number: 20110166063
    Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.
    Type: Application
    Filed: September 17, 2009
    Publication date: July 7, 2011
    Applicant: Nektar Therapeutics
    Inventors: Mary J. Bossard, Steven O. Roczniak, Harold Zappe, Yujun Wang, Ping Zhang, Dawei Sheng, C. Simone Jude-Fishburn, Elizabeth Louise Minamitani, Xiaofeng Liu, Haim Moskowitz, Dennis G. Fry, Cherie F. Ali, Christine Taylor Brew
  • Publication number: 20110160186
    Abstract: The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene.
    Type: Application
    Filed: June 9, 2009
    Publication date: June 30, 2011
    Applicant: Nektar Therapeutics
    Inventors: Michael A. Eldon, C. Simone Jude-Fishburn, Hema Gursahani, Myong Gyong Lee